Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ifinatamab deruxtecan versus docetaxel in metastatic castration-resistant prostate cancer
NL-OMON59908Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Ifinatamab deruxtecan with Docetaxel (2 arms). Primary endpoints: Overall survival and Radiographic progression-free survival. Started Jun 2025; status: recruiting.
02
Drugs
ifinatamab deruxtecandocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON59908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59908.